Combination therapy, however, which includes a BRAF or MEK inhibitor, combined with glembatumumab vedotin (an antibody drug conjugate that targets GPNMB) inhibits GPNMB and effectively controls the growth of Melanoma. This evidence concerns the gene MAP2K7 and melanoma.